➡ Merger approved with large majority by the shareholders of both companies
➡ New governance structure implemented
➡ Ambition to create a global leader in extended phage therapies to target
antimicrobial resistant pathogenic bacteria
Lyon (France) and Cambridge (MA, US), June 26, 2023 – ERYTECH (Nasdaq & Euronext: ERYP) and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR).